Haleem MS, Han L, van Hemert J, Li B, Fleming A, Pasquale LR, Song BJ. A novel adaptive deformable model for automated optic disc and cup segmentation to aid glaucoma diagnosis,. J Med Syst. 2017 Dec 7;42(1):20. doi: 10.1007/s10916-017-0859-4
Haleem MS, Han L, van Hemert J, Fleming A, Pasquale LR, Silva PS, Song BJ, Aiello LP. Regional image features model for automatic classification between normal and glaucoma in fundus and scanning laser ophthalmoscopy (SLO) images. J Med Syst. 2016 Jun 1;40(6):132. doi: 10.1007/s10916-016-0482-9
Williams VS, Nelson LM, Fehnel SE, MacDougall J, Carson RT, Tourkodimitris S, Kurtz C, Baird MJ, Johnston JM. Psychometric validation of symptom severity measures in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014 Aug;40(3):298-308. doi: 10.1111/apt.12830
Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May;39(10):1143-55. doi: 10.1111/apt.12727
Mauskopf JA, Candrilli SD, Chevrou-Severac H, Ochoa JB. Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs. World J Surg Oncol. 2012 Jul 1;10:136.
Huerta C, Rivero E, Montoro MA, García-Rodriguez LA. Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case-control study. Aliment Pharmacol Ther. 2011 Apr;33(8):969-78. doi: 10.1111/j.1365-2036
Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010 Apr 1;31(8):911-21.
Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008 Jun 15;27(12):1224-32.
Tennis P, Andrews E, Hickman P, Miller D, Hollis KA, Cook S. The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. Aliment Pharmacol Ther. 2007 Feb 1;25(3):317-22.
Miller DP, Bennett L, Hollis KA, Tennis P, Cook SF, Andrews E. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther. 2006 Sep 1;24(5):869-78.
Mangel AW, Fehnel SE. Global endpoints in functional gastrointestinal disease. Aliment Pharmacol Ther. 2005 Dec 1;22(11-12):1162-3.
Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen VZ, Hamm LR, Mangel AW, Tennis P, Cook SF. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005 Nov 10;22:935-42.
Vakil N, Hahn B, McSorley DJ. Recurrent symptoms and gastro-oesophageal reflux disease in patient with duodenal ulcer treated for helicobacter pylori infection. Aliment Pharmacol Ther. 2000 Jan;14(1):45-51.
Camilleri M, Mayer EA, Drossman DA, Heath AT, Dukes GE, McSorley DJ, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.
Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate (tritec) plus clarithromycin is effective for healing duodenal ulcers, eradicating h.pylori, and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996;10(3):251-61.